Jamil Asselah

Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial

Andrea Wang‐Gillam, Chung‐Pin Li, G. Bodoky et al. · The Lancet · 2015 · 1.2K citations

Medicine, Oncology, Pharmacology +16

Nab-paclitaxel plus gemcitabine in patients with locally advanced pancreatic cancer (LAPACT): a multicentre, open-label phase 2 study

Philip A. Philip, Jill Lacy, Fabienne Portales et al. · ˜The œLancet. Gastroenterology & hepatology · 2020 · 246 citations

Medicine, Oncology, Pharmacology +10

A systemic inflammation response index (SIRI) correlates with survival and predicts oncological outcome for mFOLFIRINOX therapy in metastatic pancreatic cancer

Vilma Pacheco-Barcía, Rebeca Mondéjar Solís, T. France et al. · Pancreatology · 2019 · 81 citations

Medicine, Immunology, Oncology +15

A Targetable EGFR-Dependent Tumor-Initiating Program in Breast Cancer

Paul Savage, Alexis Blanchet-Cohen, Timothée Revil et al. · Cell Reports · 2017 · 78 citations · Full text

Medicine, Cancer Biology, Oncology +17

Pembrolizumab for previously treated advanced anal squamous cell carcinoma: results from the non-randomised, multicohort, multicentre, phase 2 KEYNOTE-158 study

Aurélien Marabelle, Philippe A. Cassier, Marwan Fakih et al. · ˜The œLancet. Gastroenterology & hepatology · 2022 · 73 citations · Full text

Medicine, Oncology, Pharmacology +7